Lilly boosts ‘in vivo’ cell therapy capabilities with Kelonia buyout
BioPharma Dive
Worth up to $7 billion, Lilly s second recent acquisition of a company in the space is centered around a cell therapy that s currently in early-stage testing for multiple myeloma.
pharminent
April 20, 2026 (Last updated: April 20, 2026)
BioPharma Dive
Worth up to $7 billion, Lilly s second recent acquisition of a company in the space is centered around a cell therapy that s currently in early-stage testing for multiple myeloma.
